787633-87-8

Usage

Uses

Used in Pharmaceutical Research:
Benzenemethanamine, 4-chloro-3-fluoro-α-methyl-, is utilized as a research chemical for studying the effects of psychoactive substances on the central nervous system. Its potent stimulant properties allow scientists to investigate the mechanisms of action and potential therapeutic applications in various neurological and psychiatric conditions.
Used in Forensic Toxicology:
This chemical compound is employed as a reference material in forensic toxicology for the identification and analysis of controlled substances in biological samples. Its unique structure aids in the development of analytical methods and techniques for detecting and quantifying similar compounds in cases of drug abuse or poisoning.
Used in Drug Development:
Benzenemethanamine, 4-chloro-3-fluoro-α-methyl-, serves as a starting point or intermediate in the development of new pharmaceuticals with potential therapeutic benefits. Its structural modifications can lead to the discovery of safer and more effective drugs for the treatment of various disorders.

Upstream product

• 339001-14-8 1-(4-chloro-3-fluoro-phenyl)-ethanol 
• 5527-95-7 4-chloro-3-fluorobenzaldehyde 
• 787633-86-7 2-[1-(4-Chloro-3-fluoro-phenyl)-ethyl]-isoindole-1,3-dione 

Downstream Products

• 787633-88-9 N-[1-(4-chloro-3-fluoro-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 
• 900505-07-9 1-(4-chloro-5-fluoro-2-nitro-phenyl)-ethylamine 
• 900504-92-9 N-[1-(4-chloro-5-fluoro-2-nitro-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 

Relevant academic research and scientific papers

CB1 RECEPTOR MODULATORS

Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.

Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction

The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.

Substituted 1,4-diazepines and uses thereof

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined herein; X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; and R3 is —CO2Rd, —CO2M, —OH, —NHRd, —SO2Rd, —NHCONHRd, optionally-substituted amidino or optionally-substituted guanidino; or R3—X— is hydrogen or an electron pair; R4 is oxygen or —NR9R10; R5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; and R6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with Ra.